Top-Rated StocksTop-RatedNASDAQ:GH Guardant Health (GH) Stock Price, News & Analysis $23.73 -0.60 (-2.47%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$23.48▼$24.4450-Day Range$23.73▼$36.2952-Week Range$15.81▼$37.04Volume2.65 million shsAverage Volume2.08 million shsMarket Capitalization$2.90 billionP/E RatioN/ADividend YieldN/APrice Target$39.31 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get Guardant Health alerts: Email Address Guardant Health MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.94 Rating ScoreUpside/Downside65.7% Upside$39.31 Price TargetShort InterestBearish7.67% of Shares Sold ShortDividend StrengthN/ASustainability-0.51Upright™ Environmental ScoreNews Sentiment1.20Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.29) to ($3.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.27 out of 5 starsMedical Sector124th out of 910 stocksMedical Laboratories Industry5th out of 18 stocks 4.5 Analyst's Opinion Consensus RatingGuardant Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 17 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGuardant Health has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Guardant Health's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.67% of the outstanding shares of Guardant Health have been sold short.Short Interest Ratio / Days to CoverGuardant Health has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Guardant Health has recently increased by 34.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGuardant Health does not currently pay a dividend.Dividend GrowthGuardant Health does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGuardant Health has received a 71.05% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Genomics analysis tools" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Guardant Health is -0.51. Previous Next 2.3 News and Social Media Coverage News SentimentGuardant Health has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Guardant Health this week, compared to 5 articles on an average week.Search InterestOnly 7 people have searched for GH on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Guardant Health insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Guardant Health is held by insiders.Percentage Held by Institutions92.60% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Guardant Health's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Guardant Health are expected to grow in the coming year, from ($3.29) to ($3.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Guardant Health is -6.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guardant Health is -6.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Guardant Health's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. About Guardant Health Stock (NASDAQ:GH)Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Read More GH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GH Stock News HeadlinesSeptember 7 at 1:59 AM | americanbankingnews.comGuardant Health, Inc. (NASDAQ:GH) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 1, 2024 | americanbankingnews.comGuardant Health, Inc. (NASDAQ:GH) Short Interest Up 34.3% in AugustSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 29, 2024 | nasdaq.comGuardant Health Rings the Opening BellAugust 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Guardant Health Amidst Expanding MRD Market and AI IntegrationAugust 28, 2024 | finance.yahoo.comGuardant Health, Inc. (GH)August 27, 2024 | businesswire.comGuardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 26, 2024 | finance.yahoo.comDaqo New Energy, Guardant Health lower in premarket; SolarEdge, Xpeng gainSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 26, 2024 | msn.comGuardant Health falls 11% amid ATM stock sale newsAugust 26, 2024 | fool.comWhy Guardant Health Stock Just Crashed 10%August 24, 2024 | msn.comGuardant Health enters open market sale agreement for up to $400M in stockAugust 23, 2024 | fool.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtAugust 22, 2024 | stockhouse.comGuardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield(TM) Blood Test for Colorectal Cancer ScreeningAugust 22, 2024 | finance.yahoo.comGuardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer ScreeningAugust 21, 2024 | seekingalpha.comGuardant Health: Top-Line Growth Undeniable, Compounding Ability Remains UnseenAugust 19, 2024 | ca.finance.yahoo.comGH Dec 2025 15.000 callAugust 18, 2024 | finance.yahoo.comGH Sep 2024 20.000 call (GH240920C00020000)See More Headlines Receive GH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:GH CUSIPN/A CIK1576280 Webwww.guardanthealth.com Phone(855) 698-8887Fax888-974-4258Employees1,779Year FoundedN/APrice Target and Rating Average Stock Price Target$39.31 High Stock Price Target$50.00 Low Stock Price Target$27.00 Potential Upside/Downside+65.7%Consensus RatingModerate Buy Rating Score (0-4)2.94 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-479,450,000.00 Net Margins-76.23% Pretax Margin-76.15% Return on Equity-418.21% Return on Assets-27.51% Debt Debt-to-Equity Ratio16.70 Current Ratio6.40 Quick Ratio6.07 Sales & Book Value Annual Sales$643.81 million Price / Sales4.51 Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-2,373.00Miscellaneous Outstanding Shares122,369,000Free Float115,639,000Market Cap$2.90 billion OptionableNot Optionable Beta1.11 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Helmy Eltoukhy Ph.D. (Age 44)Co-Founder, Co-CEO & Chairman Comp: $11.63kDr. AmirAli Talasaz Ph.D. (Age 44)Co-CEO & Director Comp: $11.18kMr. Michael Bell (Age 55)Chief Financial Officer Comp: $630.99kMr. John G. Saia (Age 51)Chief Legal Officer & Corporate Secretary Comp: $627.18kDr. Craig Eagle M.D. (Age 57)Chief Medical Officer Comp: $649.13kMr. Christopher Freeman (Age 50)Chief Commercial Officer Comp: $630.39kMs. Darya ChudovaChief Technology OfficerMr. Kumud Kalia (Age 58)Chief Information Officer Ms. Jennifer HigginsVice President of Public AffairsMs. Terilyn Juarez Monroe (Age 57)Chief People Officer More ExecutivesKey CompetitorsGenetronNASDAQ:GTHBurning Rock BiotechNASDAQ:BNRQiagenNYSE:QGENFresenius Medical CareNYSE:FMSPACS GroupNYSE:PACSView All CompetitorsInsiders & InstitutionsTruist Financial CorpBought 8,073 shares on 8/21/2024Ownership: 0.007%Algert Global LLCBought 17,000 shares on 8/16/2024Ownership: 0.074%Creative PlanningBought 20,531 shares on 8/16/2024Ownership: 0.017%Quarry LPBought 1,527 shares on 8/16/2024Ownership: 0.001%Point72 Asia Singapore Pte. Ltd.Bought 2,464 shares on 8/15/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions GH Stock Analysis - Frequently Asked Questions How have GH shares performed this year? Guardant Health's stock was trading at $27.05 at the start of the year. Since then, GH shares have decreased by 12.3% and is now trading at $23.73. View the best growth stocks for 2024 here. How were Guardant Health's earnings last quarter? Guardant Health, Inc. (NASDAQ:GH) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.10. The business's revenue for the quarter was up 29.2% compared to the same quarter last year. What is Helmy Eltoukhy's approval rating as Guardant Health's CEO? 52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. When did Guardant Health IPO? Guardant Health (GH) raised $200 million in an IPO on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers. Who are Guardant Health's major shareholders? Guardant Health's top institutional investors include Baillie Gifford & Co. (4.98%), Bank of New York Mellon Corp (1.05%), Federated Hermes Inc. (0.70%) and Railway Pension Investments Ltd (0.51%). Insiders that own company stock include Helmy Eltoukhy, Amirali Talasaz, Amelia Merrill, Kumud Kalia, Meghan V Joyce and Stanley J Meresman. View institutional ownership trends. How do I buy shares of Guardant Health? Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Guardant Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP) and Okta (OKTA). This page (NASDAQ:GH) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guardant Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Guardant Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.